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ABSTRACT
Alzheimer’s disease is characterized by accumulation of
amyloid deposits in brain, progressive cognitive deficits and
reduced glucose utilization. Many consequences of the
disease are attributed to neuronal dysfunction, but roles
of astrocytes in its pathogenesis are not well understood.
Astrocytes are extensively coupled via gap junctions, and
abnormal trafficking of metabolites and signalling molecules
within astrocytic syncytia could alter functional interactions
among cells comprising the neurovascular unit. To evaluate
the influence of amyloid-b on astrocyte gap junctional
communication, cultured astrocytes were treated with
monomerized amyloid-b1–40 (1 mmol/l) for intervals ranging
from 2 h to 5 days, and the areas labelled by test compounds
were determined by impaling a single astrocyte with a
micropipette and diffusion of material into coupled cells.
Amyloid-b-treated astrocytes had rapid, sustained 50–70%
reductions in the area labelled by Lucifer Yellow, anionic
Alexa FluorH dyes and energy-related compounds, 6-NBDG
(a fluorescent glucose analogue), NADH and NADPH.
Amyloid-b treatment also caused a transient increase in
oxidative stress. In striking contrast with these results,
spreading of Lucifer Yellow within astrocytic networks in
brain slices from three regions of 8.5–14-month-old control
and transgenic Alzheimer’s model mice was variable,
labelling 10–2000cells; there were nostatistically significant
differences in the number of dye-labelled cells among the
groups or with age. Thus amyloid-induced dysfunction of
gap junctional communication in cultured astrocytes does
not reflect the maintenance of dye transfer through
astrocytic syncytial networks in transgenic mice; the
pathophysiology of Alzheimer’s disease is not appropriately
represented by the cell culture system.
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INTRODUCTION
Astrocytes are extensively linked to each other via gap
junctional channels formed by Cx (connexin) proteins, Cx43,
Cx30 and Cx26 (Nagy et al., 2004). These channels enable
transcellular movement of fuel, metabolites, signalling
molecules and electrolytes, with preferential transfer of
material that is governed by molecular size, charge and
connexin composition (Harris, 2007). The physiological
functions of cell-to-cell transfer of energy-related metabo-
lites within the astrocytic syncytium in brain are not well
understood, but astrocytes have important roles in brain
energetics (Hertz et al., 2007). Sharing among astrocytes of
fuel and redox compounds and rapid elimination of metabolic
by-products may be essential astrocytic responses to brain
activation. For example, the astrocytes that remove glutamate
and potassium from an active synaptic cleft incur an increased
demand for energy that would be reduced if the neurotrans-
mitters and electrolytes quickly diffuse into neighbouring
gap junction-coupled astrocytes. Also, astrocytic uptake and
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asnneuro.org / Volume 2 (4) / art:e00041 201dispersal of lactate among gap junction-coupled cells
(Gandhi et al., 2009b) in conjunction with its discharge
from perivascular endfeet that are linked to extensive gap
junctional networks (Ball et al., 2007) could serve to help
up-regulate blood flow in a larger volume of tissue com-
pared with that of focally activated cells, by raising the level
of lactate in the interstitial fluid near the endothelium
(Gordon et al., 2008). Furthermore, release from activated
astrocytes of molecules used as signals for brain imaging and
spectroscopic assays (e.g. NADH, NADPH and
14C- or
13C-
labelled metabolites of glucose or acetate) could cause
underestimation of cellular redox status and metabolic rates
calculated from accumulation of labelled products unless
appropriately taken into account.
Alzheimer’s disease is a devastating neurodegenerative
disease associated with cognitive dysfunction, increased
levels of amyloid-b deposits and neurofibrillary tangles in
brain, oxidative stress, neuroinflammation and neuronal
dysfunction (Craft, 2009; Fotuhi et al., 2009; Querfurth and
LaFerla, 2010), and one of the earliest and most reliable
markers for Alzheimer’s disease and its progression is reduced
glucose utilization in brain (Alexander et al., 2002). Astrocytic
pathology is associated with Alzheimer’s disease, including
hypertrophy, oxidative stress, DNA damage and reduced
expression of the EAAT2 glutamate transporter (Wharton
et al., 2009; Simpson et al., 2010a, 2010b). Astrocytic net-
works may be involved in the pathophysiology, since
expression of Cx43 is elevated in astrocytic processes located
in amyloid plaques in brains of Alzheimer’s patients (Nagy
et al., 1996a), and Cx43 expression is induced in gap junction-
incompetent PC12 cells after transfection with amyloid
protein (Nagy et al., 1996b). Amyloid precursor protein is
expressed in cultured astrocytes (Haass et al., 1991;
Gegelashvili et al., 1994), and astrocytes are known to bind,
take up and degrade amyloid-b (Wyss-Coray et al., 2003;
Pihlaja et al., 2008; Nielsen et al., 2009). Gap junction-
mediated calcium waves are elevated after transfection of
PC12 cells with amyloid-b or exposure of cultured astrocytes
to amyloid-b (Lynn et al. 1995; Haughey and Mattson, 2003).
In ,2-year-old transgenic mice carrying the human APP
(amyloid-b precursor protein) with the APP717VRF mutation,
gap junctional transfer of biotin was preserved, contrasting
loss of dye coupling in normal mice .1-year-old (Peters
et al., 2009). Taken together, the findings described above
suggest that astrocytic gap junctional communication may be
up-regulated in Alzheimer’s disease, and, in the present study,
we assessed gap junctional transport in cultured astrocytes
treated with amyloid-b and in brain slices from aged
transgenic mice that overexpress the human APP with the
Swedish (K670N/M671L) and Indiana (V717F) mutations
(Mucke et al., 2000). We report that treatment of cultured
astrocytes with amyloid-b markedly reduced gap junctional
transfer of six test compounds, whereas dye-transfer among
astrocytes in brain slices from three regions of transgenic
Alzheimer’s mice is similar to that of aged littermate controls,
contrasting the results of previous brain slice studies.
MATERIALS AND METHODS
Materials
DMEM (Dulbecco’s modified Eagle’s medium; catalogue number
12320-032), penicillin, streptomycin, Amphotericin B and trypsin
were obtained from Invitrogen and FBS (fetal bovine serum) was
from Hyclone. dBcAMP (dibutyryl cAMP), L-LME (L-leucine
methyl ester hydrochloride), Lucifer Yellow VS (dilithium salt),
NADH and NADPH were from Sigma–Aldrich. 6-NBDG {6-[N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-6-deoxyglucose}, A350
(Alexa FluorH 350 carboxylic acid, succinimidyl ester), A568
(Alexa FluorH 568), SR101 (sulforhodamine 101) and H2DCF-DA
(carboxydihydrodichlorofluorescein diacetate) were from
Invitrogen (Molecular Probes). Human amyloid-b1–40 (product
no. A1075, formula mass 4330 Da; Sigma) was treated with
hexafluoro-2-propanol to monomerize the amyloid-b (Klein,
2002); freeze-dried samples were stored at 280˚Ca n dd i s s o l v e d
in PBS immediately prior to use.
Astrocyte culture
Cultured astrocytes were prepared essentially as described by
Hertz et al. (1998) after harvest of cells from cerebral cortex of
1-day-old albino Wistar–Hanover rats (Taconic Farms,
Germantown, NY). Astrocytes were grown in T75 culture flasks
with DMEM containing 5.5 mmol/l glucose, 10% FBS, 50 i.u. of
penicillin and 50 mg/ml streptomycin at 37˚C in humidified air
containing 5% CO2. L-LME (0.1 mmol/l), a lysosomotrophic
agent that selectively destroys mononuclear cells including
microglia, was included in the culture medium, and cultures
were shaken by hand twice weekly to remove microglia. When
confluent, the cells were trypsinized, seeded on to polylysine-
coated glass coverslips, and grown to confluence in medium
containing Amphotericin B (2.5 mg/ml). After the cells reached
confluence, dBcAMP (0.25 mmol/l) was added to the culture
medium to induce differentiation and, starting the next day,
cells were maintained in a medium containing 0.25 mmol/l
dBcAMP plus Amphotericin Band either 5.5or 25 mmol/lglucose
for 2–3 weeks. Then the cells were treated with 1 mmol/l of
monomerized Ab1-40 or vehicle for a period ranging from 2 h
to 5 days. In our previous study which used identical
procedures, .90% of the cells expressed the astrocyte marker
GFAP (glial fibrillary acidic protein) (Gandhi et al., 2010).
Brain slices
Breeder pairs of transgenic mice (PDGF-APPSwInd, stock
#004661) that contain the human APP with Swedish
(K670N/M671L) and Indiana (V717F) mutations were purchased
from Jackson Laboratories. The mutant mouse lines originated
on a mixed C57BL/6 and DBA/2 background and were
backcrossed on to the C57BL/6J background; APP expression
is directed to neurons under the control of a human platelet-
derived growth factor b polypeptide promoter. Amyloid plaque
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and 100% at 8–10 months of age (Mucke et al., 2000). All
animal use procedures were in strict accordance with the NIH
Guide for Care and Use of Laboratory Animals and were
approved by the local Animal Care and Use Committee.
Mixed-gender heterozygous transgenic Alzheimer’s mice
and control littermates (n56/group) ranging in age from 8.5
to 14 months were anaesthetized with isofluorane, decapi-
tated, their brains were quickly removed and chilled by
immersion in oxygenated, ice-cold aCSF (artificial cerebral
spinal fluid) solution containing 26 mmol/l NaHCO3 (pH 7.3)
and 248 mmol/l sucrose, and 250 mm-thick slices were
prepared as described by Moyer and Brown (1998). Coronal
sections of brain were cut using a Leica VT 1000S tissue slicer,
slices were incubated in oxygenated aCSF containing sucrose
for 30 min at 35˚C, then for >1 h at 22˚C, and transferred to
an open bath perfusion chamber (Warner Instruments).
Gap junctional communication assays
Gap junctional communication among astrocytes was assayed
by impaling a single cell with a micropipette containing a
test compound, allowing the material to diffuse within the
astrocytic network for a fixed time (2 or 5 min in cultured cells
or brain slices respectively), then measuring the labelled
area or counting labelled cells.Micropipettes (12–14MV) were
constructed from borosilicate glass using a Sutter Instruments
P97 pipette puller and filled with the test solution. Most solu-
tionscontained21.4mmol/lKCl,0.5mmol/lCaCl2,2mmol/lMgCl 2,
5 mmol/l EGTA, 2 mmol/l ATP, 0.5 mmol/l GTP, 2 mmol/l ascor-
bate, 75 mmol/l potassium gluconate [note: potassium gluconate
was inadvertently omitted as a component of the pipette solution
in the Materials and methods of our previous studies (Gandhi
et al., 2009a, 2010)], 10 mmol/l Hepes (pH 7.2), plus a test
compound, i.e. Lucifer Yellow VS [62 mmol/l or ,4% (w/v);
excitation/emission maxima: 430/530 nm], a fluorescent
glucose analogue 6-NBDG (20 mmol/l; 475/550 nm), A350
(5 mmol/l; 346/442 nm), A568 (5 mmol/l; 578/603 nm) or
NADH or NADPH (25 mmol/l; 340/460 nm). Lucifer Yellow VS
solutions for use in brain slices contained 124 mmol/l Lucifer
Yellow, 10 mmol/l Hepes (pH 7.2), 48 mmol/l LiCl and 0.001%
Evans Blue plus 0.01% albumin; the Evans Blue–albumin was
added so that the pipette could be visualized when impaling
SR101-labelled astrocytes in brain slices. For assays of 6-NBDG
gap junctional transfer, efflux of the fluorescent tracer from
astrocytesviaglucosetransporterswasblockedbycytochalasin
B, a glucose transport inhibitor (Speizer et al. 1985); we pre-
viously observed that glucose transporter-mediated efflux of
the NBDG reduced the NBDG-labelled area by ,50% (Gandhi
et al., 2009a). For these assays, the perfusion medium
contained 10 mmol/l cytochalasin B, 10 mmol/l glucose (to
compete for re-uptake of any tracer that leaked out of cells)
and an excess level of pyruvate (10 mmol/l) was included as
oxidative fuel to compensate for glucose transport blockade
during dye-transfer assays. The osmolarity of each pipette
solution was measured (Osmette II, Precision Systems) and
adjusted to 305–320 mOsm/l with sucrose or deionized water,
as appropriate.
Cultured astrocytes and slices from mouse brain were
transferred to the microscope stage and perfused at 1 ml/min
with freshly prepared aCSF containing 26 mmol/l NaHCO3 (pH
7.3) and 10 mmol/l glucose at room temperature (,20–22˚C),
and continuously bubbled with O2/CO2 (95/5%). Cultured
astrocytes were visualized under differential interference
contrast with a Nikon Eclipse E600 microscope using a Photo-
metrics CoolSNAP ES camera (Roper Scientific) and MetaVue
software (Molecular Devices). Astrocytes in slices of hippocam-
pus,cerebralcortexand inferiorcolliculussliceswereidentified
by their specific labelling by SR101(Nimmerjahn et al., 2004;
Ball et al., 2007); SR101 (60 mmol/l) was included in the final
aCSF solution for slice recovery. Single astrocytes were impaled
with micropipettes using a MP-225 manipulator (Sutter
Instruments), and tracers were diffused for 2 min into cultured
astrocytes or for 5 min into astrocytes in brain slices before the
micropipette was removed. Separate groups of control
astrocytes grown in low glucose were assayed for dye transfer
with and without pretreatment with 0.6 mmol/l octanol for
10 min to inhibit gap junctional transfer. Fluorescence was
determined before (background) and immediately after
diffusion of the test compound into a single astrocyte, and
the areas labelled by the probes were determined with
MetaVue software. Further details of the experimental
procedures are described in our previous studies (Ball et al.,
2007; Gandhi et al., 2009a; Gandhi et al., 2010).
Countsofthenumberofdye-labelledcellsinbrainsliceswere
carried out as follows. The 250 mm-thick brain slices that
were previously injectedwith Lucifer Yellow were removed from
themicroscopestageandimmediatelyfixedbyimmersionin4%
paraformaldehyde in PBS (pH 7.4), quickly followed by mixing
for 30 s, then gentle shaking for 30 min at room temperature
(approx. 20˚C) before being stored at 4˚C. Prior to sectioning, the
slices were rinsed in PBS, cryoprotected in 20% sucrose/PBS
at 4˚C, frozen and cut into 7 mm-thick serial sections at 220˚C.
Sections were mounted on SuperfrostPlus glass slides, air dried
f o r2 4ha n dt h e ns t o r e di ns l i d eb o x e sa t4˚C. After the sections
were coverslipped (Gelmount medium and glass coverslips),
the Lucifer-Yellow-containing astrocytes were counted in each
7 mm-thick serial section using a Zeiss Axioskope2 with Zeiss
Plan Neofluar objectives (610/0.30 numerical aperture or
620/0.50), an MTI CD72 camera and an MCID
TM Imaging
System (InterFocus Imaging Limited), then summed to obtain
the total number of dye-labelled cells for each 250 mm-thick
brain slice.
Congo Red staining of amyloid plaques
An alkaline Congo Red staining method (Puchtler et al., 1962;
Wilcock et al., 2006) was used to identify amyloid plaques
in the mouse brain tissue. After the Lucifer Yellow-labelled
cells were counted, the coverslips were removed from the
slides by soaking in water overnight, then rinsed several times
to remove any remaining Gelmount. Next, the tissue sections
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203were soaked in deionized water for 30 s, transferred to Gill’s
Haematoxylin #3 (Polysciences Incorporated) for 30 s, and
rinsed in tap water until the water was clear. A critical aspect
of the Congo Red staining procedure was that each of the
two alkaline solutions was freshly prepared and used within
15 min. The pretreatment solution was prepared by adding
2.5 ml of 1% (w/v) aqueous NaOH to 250 ml of previously
prepared NaCl-saturated 80% ethanol; then the solution
was mixed and filtered. The staining solution was similarly
prepared by adding the NaOH to a 0.2% Congo Red (Chroma
#10460) solution in 80% ethanol saturated with NaCl. The
slides were first incubated for 20 min in the pretreatment
solution, placed in the staining solution for 20 min, then
quickly passed through three changes of absolute ethanol
followed by three changes of xylene and mounted with
Permount medium (Fisher Chemical). Brightfield and fluor-
escent images of the Congo Red-stained tissue (Puchtler and
Sweat, 1965) were obtained and composite images (6100
and 6200 magnification) were produced by overlaying the
brightfield images with their corresponding colorized fluor-
escent images. The presence of amyloid plaques was
confirmed by microscopic examination under cross-polarized
light and demonstration of red–green birefringence (Jin et al.,
2003 and references cited therein).
Assay for ROS (reactive oxygen species)/RNS
(reactive nitrogen species)
H2DCF-DA is cell-membrane-permeable, cleaved by intracel-
lular esterases and, after oxidation mediated mainly by H2O2
and peroxynitrite, becomes fluorescent DCF (dichlorofluor-
escein) (Cruthirds et al., 2005). H2DCF-DA (10 mmol/l) was
added to the culture medium, cells returned to the CO2
incubator for 30 min at 37˚C, cells washed with perfusion
solution and fluorescence intensity determined with Nikon
E600 microscope and MetaVue software.
Statistics
All statistical analyses were performed with GraphPad PrismH
software, version 5.02 (GraphPad Software). Comparisons
between two groups of independent samples were made with
two-tailed, unpaired t tests. P,0.05 is considered to be
statistically significant. Reported values are means and
vertical error bars in Figures represent 1 S.D.
RESULTS
Amyloid-b reduces Lucifer Yellow transfer
through gap junctions in cultured astrocytes
Previous studies of glutamate uptake, signalling pathways
and oxidative stress (Matos et al., 2008) and calcium waves
(Haughey and Mattson, 2003; Chow et al., 2010) exposed
cultured astrocytes to 5 mmol/l amyloid-b1–40or amyloid-b1–42
for various time intervals; this dose is considered to be the
most likely level of astrocytic exposure in Alzheimer’s brain
(Haughey and Mattson, 2003). A higher level of amyloid-
b25–35 (20 mmol/l) has been used to evaluate effects on gap
junctional inhibition by cytokines released by microglia (Me ˆme
et al., 2006). The 5 mmol/l dose of amyloid-b1–42 was stated to
be non-toxic to astrocytes within the 24 h (Haughey and
Mattson, 2003), but even much lower doses (10 or 100 nmol/l
and 1 mmol/l) of amyloid-b1–40 enhanced the generation of
ROS and advanced glycation end-products in vascular
endothelial cells grown in high (25 mmol/l) compared with
low (5 mmol/l) glucose (Burdo et al., 2009). ‘Aged’ solutions of
amyloid-b1–40 and amyloid-b1–42 in which oligomer and
fibrillary aggregates of the peptide are formed are also non-
toxic in the range 1–10 mmol/l, but do stimulate oxidative
stress in astrocytes grown in high-glucose DMEM (Matos et al.,
2008); aged amyloid also reduces free intracellular calcium
levels in astrocytes, alters their morphology and increases
expression of immunoreactive S100b and GFAP (Meske et al.,
1998). In our initial studies, dye transfer was tested with 1, 2, 5
or 10 mmol/l of monomerized amyloid-b1–40, and the lowest
dose was chosen for use to minimize formation of vacuoles
that were visible in cells given the highest doses. The effects of
amyloid-b1–40 were first assessed in cultured astrocytes grown
in low (5.5 mmol/l) or high (25 mmol/l) glucose because we
recently found that experimental diabetes, a risk factor for
Alzheimer’s disease, reduces dye transfer through gap junc-
tions in cultured astrocytes and STZ (streptozotocin)-diabetic
rats (Gandhi et al., 2010), and STZ-induced diabetes also
enhances cognitive deficits and expression of oxidative stress
markers in presymptomatic Alzheimer’s transgenic mice (Burdo
et al., 2009).
In agreement with our previous results, the spread of Lucifer
Yellow through gap junctions was much greater in cells grown
in low (Figures 1Aa and 1Ab) compared with high (Figures 1Bd
and 1Be) glucose. Treatment of both culture groups with
1 mmol/l monomerized amyloid-b for 2 h markedly reduced
dye transfer compared with their respective controls
(Figures 1Ac and 1Bf). This decrement averaged approx. 50–
75% in astrocytes grown in low (Figure 2A) or high (Figure 2B)
glucose compared with paired control cultures. Pretreatment
of low-glucose control astrocytes with octanol reduced
the Lucifer Yellow-labelled area by approx. 75% (P,0.001),
from 11220¡4566 mm
2 (mean¡S.D.) to 2913¡950 mm
2,
a magnitude similar to that caused by amyloid treatment.
Maximal inhibition of dye transfer by amyloid-b occurred
within 2 h, and increased duration of exposure to the single
dose of monomerized amyloid from 2 h to 5 days did not
alter the decrement (Figure 2); no attempt was made to
determine theproportion ofamyloidmonomers,oligomersand
fibrils over time. Because high glucose reduced dye transfer in
control cultures and blunted the percentage change after
amyloid-b treatment (Figure 2), all subsequent assays used
astrocytes grown in low glucose.
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stress in astrocytes grown in low glucose
We previously identified oxidative stress as a probable
causative factor in disruption of trafficking of small
molecules through the astrocytic network in experimental
diabetes (Gandhi et al., 2010), and amyloid-b exacerbates the
generation of ROS in brain vascular endothelial cells (Burdo
et al., 2009). DCF fluorescence was, therefore, assayed to
evaluate the extent of amyloid-b-induced oxidative stress in
the low-glucose cultures. DCF fluorescence approximately
doubled after 2 h exposure to amyloid-b, but the increase did
not persist at 24 h, and a slight decrement was evident at 5
days (Figure 3). The rapid onset of reduced dye transfer
(Figures 1 and 2) and low, transient increase in oxidative
stress with amyloid treatment (Figure 3) sharply contrast
the responses of hyperglycaemic astrocytes. These cells had
a rapid, progressive rise in DCF fluorescence, but there was a
3–5 day delay before the onset of inhibition of dye transfer,
suggesting that other factors mediate the effects of amyloid-
b on dye transfer.
Amyloid-b impairs gap junctional transfer of
compounds with different size or charge
Cell-to-cell transfer of anionic dyes that are either larger
(A568, 730 Da; Figures 4a and 4b) or smaller (A350, 311 Da
when ionized; Figures 4c and 4d) than Lucifer Yellow VS (536
Da when ionized; Figures 1 and 2) is also markedly lowered by
amyloid-b treatment. The area labelled by A568 was reduced
within 2 h by amyloid-b and it persisted at 1 and 2 days
(Figure 5A), whereas that labelled by A350 was statistically
significantly only at day one due to lower values for the
control group in the 2 day treatment group (Figure 5B).
Octanol treatment of control astrocytes reduced the A568-




Diffusion within the astrocytic network of molecules
related to glucose metabolism was also inhibited by
amyloid-b. The area labelled by 6-NBDG (342 Da), a non-
phosphorylatable uncharged fluorescent analogue of glucose
(Aller et al. 1997; Speizer et al.1985) that is used to assay
transport, was reduced by 40–70% after 1–2 days treatment
of astrocytes with amyloid-b (Figure 6A). NADH and NADPH
are phosphorylated anions involved in redox reactions in the
glycolytic and pentose phosphate shunt pathways respect-
ively. Movement of NADH (663 Da) within the astrocytic
syncytium was depressed after exposure to amyloid-b for 2 h
to 2 days (Figure 6B), and spreading of NADPH (723 Da) was
also reduced by 24 h treatment with amyloid-b (data not
shown). Octanol pretreatment of control astrocytes reduced
NBDG labelling from 12816¡4305 mm
2 to 1153¡492 mm
2
(P,0.001) and diminished NADH labelling from 6109¡2873
mm
2 to 1323¡519 mm
2 (P,0.01).
Astrocytic dye transfer in brain slices from aged
control and Alzheimer’s mice
Because cultured astrocytes are not exposed to the same
environment as cells in the aging and Alzheimer’s model
mouse brain, Lucifer Yellow transfer was also assayed in 8.5–
14-month-old transgenic mice that overexpress mutant
human APP and in age-matched littermate controls. Mice
with the mutant APP were identified by genotyping, and
amyloid plaque formation was verified in all animals
designated as ‘Alzheimer’s mice’ after the dye-labelled cells
were counted. Congo Red-stained amyloid plaques were
Figure 1 Representative images of reduced Lucifer Yellow spread among astrocytes after brief exposure to amyloid-b
Cultured astrocytes grown in (A) low (5.5 mmol/l) or (B) high (25 mmol/l) glucose-containing medium for 2–3 weeks. Cells were
visualized and impaled with a micropipette (a and d), and Lucifer Yellow was diffused for 2 min into a single astrocyte in a culture
treated with vehicle (b and e) or with 1 mmol/l of amyloid-b1–40 for 2 h prior to analysis (c and f). Scale bars indicated apply to all
panels.
Amyloid-b and astrocytic networks
E 2010 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
205readily detected in parenchyma and perivascular space in
hippocampus (Figure 7A) and cerebral cortex (Figure 7B) of
transgenic mice. Some perivascular staining, but not Congo
Red-stained plaques in parenchyma, was detected in the
inferior colliculus of APP mice (Figure 7C). However, this does
not rule out the presence of amyloid plaques in this structure,
since a higher-sensitivity method to detect immunoreactive
amyloid protein was not used. Because Congo Red can also
bind to non-amyloid substances and some small red-stained
areas (data not shown) were observed in white matter and in
control brain, Congo Red-stained plaques were also examined
by polarized microscopy; the plaques exhibited red–green
birefringence (data not shown) which is characteristic of
amyloid deposits (Jin et al., 2003).
Astrocytes in slices of hippocampus (Figure 8a), cerebral
cortex and inferior colliculus from mixed-gender control and
Alzheimer’s mice were identified as SR101-positive cells
(Nimmerjahn et al., 2004; Ball et al., 2007), then a single
astrocyte was impaled with a micropipette (Figure 8b)
containing Lucifer Yellow VS (Figure 8c), and the dye was
allowed to diffuse into the astrocytic syncytium for 5 min.
Many dye-labelled astrocytes were readily detected in the 7
mm-thick serial sections of the 250 mm-thick slices from all
three brain structures of Alzheimer’s and control mice. The
labelling patterns differed in the three brain structures
(Figures 8d–8f), although there was also some within-
structure variation due to the exact location of the impaled
astrocyte in each structure. In the hippocampus, labelling
derived from impaled astrocytes located near the pyramidal
neuronal layer was prominent and most dense in the
astrocytes along the pyramidal neuronal layer, with labelled
cells above and below the pyramidal layer (Figure 8d). In
contrast, dye spread among astrocytes in the cerebral cortex
caused labelling of cells in an approximate circular pattern
around the impaled cell (Figure 8e). Astrocytic labelling in the
Figure 2 Amyloid-b treatment reduces gap junctional spreading of Lucifer
Yellow in low- and high-glucose astrocyte cultures
Cultured astrocytes grown in low (A) or high (B) glucose were treated with
1 mmol/l monomerized amyloid-b1–40 or vehicle for up to 5 days prior to
assay of the Lucifer Yellow-labelled area (see Figure 1). The number of
injected cells for the control and amyloid-b-treated groups respectively, at
each time point are as follows: (A)2h ,n56, 5; 5 days, n55, 6; (B)2h ,n59,
9; 1 day, n510, 11; 2 days, n514, 14.
Figure 3 DCF fluorescence in amyloid-b-treated astrocytes
Cultured astrocytes grown in low-glucose medium for 2–3 weeks were
treated with 1 mmol/l monomerized amyloid-b1–40 or vehicle for up to 5 days.
The number of injected cells for the control and amyloid-treated groups
respectively at each time point are as follows: 2 h, n516, 16; 1 day, n511,
12; 5 days, n510, 10.
Figure 4 Representative images of impaired Alexa FluorH dye spread
among astrocytes after brief exposure to amyloid-b
Cultured astrocytes grown in low-glucose medium for 2–3 weeks were
treated with vehicle (a and c)o r1mmol/l monomerized amyloid-b1–40 for
48 h (b and d) prior to assay of dye spreading after diffusion of tracer into a
single cell. Scale bars shown apply to all panels.
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(Figures 8f), but most of the 250 mm-thick sections (data not
shown) had a radial labelling pattern that extended from the
injected cell towards the meningeal boundary, as we
previously observed (Ball et al., 2007).
The total number of dye-labelled cells was quite variable in
both control and APP mice, ranging from a low of approx.
ten, up to several thousand coupled cells, with no statistically
significant differences in the number of dye-labelled cells in
control and APP mice for any of the three brain regions
(Figure 9). When data from all slices from all animals were
plotted as a function of age, there were no obvious age-
dependent trends over the relatively narrow range of ages of
mice used in the present study; control and APP mice had
variable and overlapping numbers of dye-labelled cells
(Figure 10). Unfortunately, the number of APP mice available
for this study was limited by breeding problems that persisted
over approx. 2 years of the funding period; this issue reduced
the number of ages and number of regional brain slices
that were assessed, as well as the scope of planned work
which included evaluation of gap junctional trafficking of
endogenous metabolites and local rates of glucose utilization
during brain activation.
DISCUSSION
Discordant results in tissue culture and brain
slices: complications can arise from severe
hyperglycaemia
The major finding of the present study is that exposure of
cultured cerebral cortical astrocytes to low-dose monomer-
ized amyloid-b1–40 markedly impaired transfer of material
within the syncytial network, but dye transfer was unaffected
in aged transgenic mice overexpressing amyloid protein. In
low-glucose cultures, amyloid-b treatment affected transcel-
lular diffusion of six anionic and neutral compounds with
Figure 5 Amyloid-b impairs trafficking of large and small Alexa FluorH
dyes
Cultured astrocytes grown in low-glucose medium for 2–3 weeks were
treated with 1 mmol/l monomerized amyloid-b1–40 or vehicle for up to 2 days
prior to assay of the labelled area by (A) A568 or (B) A350 that was diffused
for 2 min into a single cell. The number of injected cells for the control and
amyloid-treated groups respectively, at each time point are as follows: (A)
2h ,n537, 41; 1 day, n561, 61; 2 days, 31, 48; (B)2h ,n513, 16; 2 days,
n516, 19.
Figure 6 Amyloid-b reduces syncytial distribution of energy-related
molecules
Cultured astrocytes grown in low-glucose medium for 2–3 weeks were
treated with 1 mmol/l monomerized amyloid-b1–40 or vehicle for up to 2 days
prior to assay of the labelled area by (A) 6-NBDG, a fluorescent glucose
analogue (molecular mass, 342 Da) or (B) NADH (molecular mass, 663 Da)
which was diffused into a single astrocyte. The number of injected cells for
the control and amyloid-treated groups respectively, at each time point are
as follows: (A) 1 day, n512, 16; 2 days, n516, 19; (B)2h ,n537, 41; 1 day,
61, 61; 2 days, n530, 48.
Amyloid-b and astrocytic networks
E 2010 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
207molecular masses ranging from approx. 350 to 700 Daltons; it
had a rapid onset (within 2 h), it was accompanied by modest,
transient oxidative stress and the inhibition was sustained for
at least 5 days after a single treatment (Figures 1–6). Because
transcellular movement of NADH, NADPH and 6-NBDG were
reduced by amyloid treatment, signals used to monitor redox
status and glucose transport and utilization are affected and
could influence metabolic studies, particularly in cultured
astrocytes. Amyloid-b depressed gap junctional trafficking to
a similar level in high- and low-glucose cultures, but those
grown in high glucose had a smaller overall percentage
decrease (Figures 1 and 2) owing to reduced dye transfer
among the severely hyperglycaemic cells (Gandhi et al., 2010,
Thi et al., 2010).
Diabetes is a risk factor that exacerbates pathophysiological
changes in Alzheimer’s transgenic mice and cultured cells, with
synergistic interactions that increase generation of advanced
glycation products and ROS and diminish cognitive function
(Burdo et al., 2009). STZ-diabetic rats have elevated levels of
amyloid-b in brain (Li et al., 2007; Liu et al., 2008), but, to our
knowledge, gap junctional trafficking has not been evaluated
in a diabetic-Alzheimer’s rodent model. Interpretation of the
inhibitory effects on glucose metabolic pathways, glutamate
uptake, signalling pathways, gap junctional communication
and other processes that have been ascribed to amyloid
peptides in other studies are complicated by the use of
astrocytes that were cultured in media containing 25–40
mmol/l glucose (Parpura-Gill et al., 1997; Me ˆme et al., 2006;
Matos et al., 2008; Allaman et al., 2010) or by lack of
information regarding medium glucose concentration (Meske
et al., 1998; Haughy and Mattson, 2003; Chow et al., 2010). A
glucose level of 25 mmol/l is approx. 10-fold greater than that
in normal rat brain, and it exceeds that in diabetic rat brain by
3.6-fold; it is well known that prolonged hyperglycaemia
causes oxidative stress, glycation reactions and sorbitol
production (Gandhi et al., 2010 and references cited therein).
In fact, astrocytes grown in high-glucose medium oxidize
glucose and lactate at a rate half that of those grown in
low glucose (Abe et al., 2006). Exposure to amyloid peptides
and amyloid aggregates has deleterious consequences for
cultured astrocytes and neurons, but the possibility of
synergistic interactions of amyloid treatment with severely
Figure 7 Amyloid deposits in parenchyma and perivascular space of Alzheimer’s transgenic mice
Brain sections from anterior dorsal hippocampus (A), anterior cerebral cortex (B) and inferior colliculus (C) from each of the aged
control and transgenic mice were stained with haematoxylin and Congo Red after dye-labelled cells were counted. Control mice (a, d
and g) had no amyloid plaques, whereas plaques (vertical arrows: b, c, d and f) were present in hippocampus and cerebral cortex of all
transgenic mice. Perivascular amyloid deposits (horizontal arrows) are visible in cross-sectional views of blood vessels (b, e and h).
The horizontal arrow in (c) indicates an artefact owing to folded tissue. Two representative images from each brain region from
different transgenic mice are illustrated for each brain region. Panel (e) is close to the midline of the brain and perivascular labelling
is in the meninges between the two hemispheres; in hippocampus panels (a) and (c), ‘p’ denotes the pyramidal neuronal layer. The
scale bar shown applies to all panels.
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examined and clarified.
Influence of inflammation, calcium level and age
or brain region on dye coupling.
Rapid and sustained down-regulation of dye spread among
cultured astrocytes by amyloid-b1–40 contrasts the results of
Me ˆme et al. (2006), who found no effect of amyloid-b25–35
on Lucifer Yellow diffusion through gap junctions in scrape-
load assays; this smaller peptide did, however, enhance the
inhibitory effects of cytokines released from LPS (lipopoly-
saccharide)-activated microglia that were grown in mixed
cultures with astrocytes (38% microglia). Notably, non-
activated mixed cultures had similar dye-labelled areas as
astrocyte cultures (Me ˆme et al., 2006), suggesting that any
microglia that remained in our non-activated astrocyte
cultures (.90% are GFAP-positive cells) are unlikely to have
contributed to dye-transfer inhibition.
High calcium levels can close gap junctions, but the
physiological relevance of the level required is not clear
(Rozental et al., 2001). Amyloid peptides are thought to form
calcium channels in the astrocytic membrane, giving rise
to intracellular calcium signals and oxidative stress due to
activation of NADPH oxidase (Abramov et al., 2004). Exposure
of astrocytes to amyloid-b1–42 increases intracellular calcium
concentration, as well as the amplitude, velocity and travel
distance of mechanically induced calcium waves (Haughey
and Mattson, 2003). Acute dosing with amyloid-b1–40 causes
Figure 8 Representative images of Lucifer Yellow diffusion among
astrocytes in slices from three brain regions of aged Alzheimer’s transgenic
mice
Brain slices (250 mm thick) were prepared from hippocampus (a–b), cerebral
cortex (e) and inferior colliculus (f) of aged Alzheimer’s transgenic mice.
Astrocytes were identified as sulforhodamine-positive cells (a), then impaled
with a micropipette (b) containing Lucifer Yellow that was allowed to diffuse
into the astrocyte for 5 min (c). Then the sections were immediately fixed,
cut into 7 mm-thick serial sections and dye-labelled cells counted in each
section from each slice. Fluorescence images of typical sections are shown for
each brain region to illustrate the different patterns of dye-labelled cells
(bright spots) derived from impaling an astrocyte near the pyramidal neuronal
layer in the hippocampus (d), or an astrocyte in cerebral cortex (e) and inferior
colliculus(f).Arrowheads in(a),(c)and(d)denotedarkspacescorrespondingto
unlabelled neuronal cell bodies. The scale bar in (a) also applies to (c).
Figure 9 Dye transfer in brain regions in slices from aged control and
Alzheimer’s mice
Total number of Lucifer-Yellow-labelled cells in three brain regions (A, B and
C) from control and Alzheimer’s transgenic mice ranging in age from 8.5 to
14 months. Each point represent one brain slice; 1–3 slices were obtained
from each region of six control and six transgenic mice. The number of slices
for inferior colliculus, cerebral cortex and hippocampus respectively, were:
controls, 10, 5, 6; transgenic, 10, 5, 5. Note that two of the control cortical
slices had similar numbers of labelled cells and the values in the Figure
overlap. There were no statistically significant differences between the
control and experimental groups in each region.
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209time-delayed spontaneous calcium waves (Chow et al., 2010),
whereas various ‘aged’ amyloid peptide preparations reduce
intracellular calcium level in a dose- and time-dependent
manner (Meske et al., 1998). In our gap junction assay
procedure, impaling an astrocyte would initiate calcium
waves, but dye spread does occur in control and amyloid-
treated cells, and the contribution of calcium to differential
channel closure in these two groups of cells, if any, is not
clear. Other factors, such as amyloid-induced alterations in
membranes that may modify Cx function or level, altered
signalling cascades, and shifts in gene expression, may also be
involved at different times after addition of monomerized
amyloid-b1–40.Thebasisfortheinhibitorybioactivityofamyloid-b
on gap junctions in cultured astrocytes remains to be
established in future studies.
Surprisingly, the robust blockade of dye transfer within
networks of amyloid-b-treated cultured cerebral cortical
astrocytes did not occur in cerebral cortex, hippocampus or
inferiorcolliculusofAPP-transgenicmice(Figures 8–10).These
findings indicate that: (i) amyloid treatment alone is not
sufficient to represent the more complex pathophysiology of
astrocyticnetworks in theaged APPmouse brain, (ii) there may
be compensatory responses that maintains syncytial connec-
tivity in APP mouse brain, beyond the localized up-regulation
of immunoreactive Cx43 observed in human amyloid plaques
(Nagy et al., 1996a) and (iii) global compared with regional
differences do not explain the different results in cultured cells
and brain slices. Discordant results in tissue culture-brain slice
assays were not, however, an issue in our recent study of
experimental diabetes, in which both model systems exhibited
reduced dye coupling and increased oxidative stress in spite of
large differences in glucose level, time of exposure to high
glucose and syncytial size (Gandhi et al., 2010). In the diabetic
ratliterature,plasma andbrainglucoselevelsriseanaverageof
approx. 3-fold to 27 and 7 mmol/l respectively (Gandhi et al.,
2010), and the normal adult rat inferior colliculus has up to
approx. 12000 dye-coupled cells compared with 10–20 cells in
cultured cortical astrocytes (Ball et al., 2007 and references
cited therein). In the present study, most slices from aged
control and APP mice had .100 coupled cells, with an average
regional number of dye-coupled cells ranging from approx.
300 to 1100 (Figures 9 and 10), values that are much lower
than in young adult rats. Peters et al. (2009) recently
characterized properties of astrocytes in aged Alzheimer’s
transgenic mice and observed modest syncytial labelling
(#114 cells) with biocytin [molecular mass 372 Da; diffused
into cells for 20 min via patch clamp pipettes containing a
0.5% (13 mmol/l) solution] in young control mice and aged
Alzheimer’s mice, with no apparent relationship to distance of
the injected cell from an amyloid plaque. In contrast, their
aged control mice (.12 months) had no detectable networks
in cerebralcortexandonly three outof20cells inhippocampal
slices werecoupled.Thereasons for lower couplingin aged APP
mice and very poor dye transfer in their aged controls are
not known. Conceivably, differences might arise from the
genotype of the mice used in the studies by Peters et al. (2009)
and by us, or from age-related differences in transfer of
biocytin compared with Lucifer Yellow VS. Also, it is important
to recognize that changes in transfer of a specific dye do not
necessarily predict the passage of other compounds. For
example, when diffused into single astrocytes in culture or in
brain slices, hexose-6-phosphates are very poorly transferred
through gap junctions compared with various fluorescent dyes
that were used as internal permeant standards in the same
assays (Gandhi et al., 2009a). Our dye-transfer assays used high
concentrations of Lucifer Yellow VS to maximize sensitivity for
detection of astrocytic coupling and to more easily count
labelled cells in brain slices, since dye-labelled nuclei are more
prominent with Lucifer Yellow VS compared with Lucifer
Yellow CH. Dye leakage from impaled cells is unlikely to cause
significant labelling due to washout via the perfusion
solution and to negligible labelling by extracellular mem-
brane-impermeant dye; labelling of brain slices caused by
micropipette insertion or by damaging an impaled cell is very
low. Also, in our previous studies, Lucifer Yellow labelling of
cultured astrocytes located at some distance from the scrape-
load site was negligible (Gandhi et al., 2010), and efflux of
Lucifer Yellow (and, by inference, uptake from extracellular
sources) from pre-loaded cells was not detectable unless cells
were exposed to a divalent-cation-deficient medium to open
‘hemichannel’ or pannexin pores (Gandhi et al., 2009a). To
summarize, astrocytic gap junctional communication in
different model systems for Alzheimer’s disease varies
considerably, and in vivo responses may be influenced by
amyloid burden, age, local cytokine level, oxidative stress and
other unidentified factors.
Metabolite trafficking and brain imaging in
Alzheimer’s disease
The hippocampus and cerebral cortex are involved in memory
and cognition, and these brain regions are, therefore,
Figure 10 Dye transfer as function of age in control and Alzheimer’s mice
Values from all structures and all slices in Figure 9 are plotted as a function
of age of the animal.
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Alzheimer’s disease and loss of higher brain function.
However, other brain systems are also involved in the disease,
and, for example, Alzheimer’s patients have hearing impair-
ment (Palmer et al., 1999) and abnormal auditory evoked
potentials and latency responses associated with midbrain–
brainstem auditory processing (O’Mahony et al., 1994). The
inferior colliculus, an auditory structure with the highest
metabolic rate in brain (Sokoloff et al., 1977), has amyloid
plaques (Sinha et al. 1993) and a lower level of cytochrome
oxidase (Gonzalez-Lima et al. 1997), indicating a reduced
capacity for oxygen utilization. Dye transfer was therefore
examined in these three brain structures after testing a
variety of fluorescent compounds in tissue culture. Assay of
local rates of glucose utilization using [
18F]FDG-PET
([
18F]fluorodeoxyglucose-positron emission tomography) has
been an important tool to evaluate the progression and
treatment of Alzheimer’s disease (Alexander et al., 2002), and
magnetic resonance spectroscopic studies using [
13C]glucose
are increasingly used to study brain diseases because fluxes of
labelled carbon into different pathways can be evaluated.
Progressive mitochondrial dysfunction and impaired oxidative
metabolism of glucose in brain of Alzheimer’s patients
(Gibson et al., 2008) would increase lactate production and
release from brain. Incomplete retention of labelled lactate
and other diffusible compounds in regions of interest during
metabolic assays would contribute to underestimation of
glucose utilization rates determined with labelled glucose
compared with fluorodeoxyglucose, the products of which
are phosphorylated and trapped intracellularly. Also, increases
in glycolytic flux in the early stages of the disease to
compensate for energy deficits arising from mitochondrial
damage could give the false impression that cellular function
is normal, when, in fact, cellular damage is evolving, and
by the time glucose utilization rates fall, the damage may
be irreversible or reflect cell death. For these reasons, it is
particularly important to use different approaches to
evaluate functional metabolism in diseased brain. Our
previous studies have focused on evaluating the cellular
contributions to discordant images of auditory activation in
rats derived from labelled glucose and deoxyglucose (Cruz
et al., 2007). The results strongly support the conclusions
that: (i) lactate release from activated brain accounts for
most of the ‘missing’ glucose metabolites, (ii) lactate
transporters and astrocytic gap junctional trafficking are
involved in this process and (iii) release of some glucose,
lactate, other metabolites and amyloid-b occurs by lymphatic
drainage from the inferior colliculus through perivascular
channels to the cervical lymph nodes (Dienel and Cruz, 2008;
Gandhi et al., 2009a, 2009b; Ball et al., 2010). Amyloid
deposits accumulate in the parenchyma and perivascular
space in brain of animals with Alzheimer traits (e.g. Figure 7)
and in Alzheimer’s patients, and partial blockade of
perivascular fluid flow is postulated to contribute to the
pathophysiology of Alzheimer’s disease (Carare et al., 2008;
Weller et al., 2008). In diabetic patients, cerebrovascular
disease and thickening of the extracellular matrix would
exacerbate this condition by impairing vascular elasticity,
diminishing arterial pulsations that power perivascular fluid
flow and reducing the distribution within brain of fuel,
signalling molecules, neurotransmitters and electrolytes, as
well as clearance of metabolic by-products from activated
regions. Further work is necessary to: (i) evaluate astrocytic
networks in aged control brain compared with aged
Alzheimer’s brain and (ii) determine whether changes in
metabolite trafficking and functions of the neurovascular
unit (i.e. interactions of astrocytes, neurons and endothelial
cells involved in cerebrovascular and metabolic regulation)
influence the outcome and interpretation of brain imaging
and spectroscopic studies in Alzheimer’s patients.
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